|
|
Post by mannmade on Nov 8, 2019 10:23:11 GMT -5
I was speaking with a person the other day, when she mentioned her 22 year old daughter has been a T1 since she was 4. When I asked how she was doing, she said good days and bad days and being a new mother it was often very difficult to handle both a newborn and her own diabetes. I asked if she was on a pump and was told that she went off the pump last year after a near death hypo due to a malfunction in the pump and that now she was doing MDI.
I am sure you all know where this is going... when I mentioned Afrezza and all the benefits she could not beleive it! She had never heard of Afrezza. Immediately she put her daughter on the phone with her and as I described all the beneifits of using a CGM with Tresiba and Afrezza, the daughter started to cry as she had never heard of Afrezza and could not beleive there was a product out there that could change her life so drastically and improve her long term health prospects.
So I am now going to drive 90 miles one way this weekend to visit them and give them a presentation and educate them before they go ask their doctor, just to make sure they are armed and eduated with enough information to push for Afrezza. One of the prime sources I have referred them to is AfrezzaJustBreathe, so thank you Compound for keeping it going...
The Good and the Bad of this story is the obvious, and it is a story that seems to constantly be repeated... Enough said! GLTAL's
|
|
|
|
Post by peppy on Nov 8, 2019 10:27:13 GMT -5
I was speaking with a person the other day, when she mentioned her 22 year old daughter has been a T1 since she was 4. When I asked how she was doing, she said good days and bad days and being a new mother it was often very difficult to handle both a newborn and her own diabetes. I asked if she was on a pump and was told that she went off the pump last year after a near death hypo due to a malfunction in the pump and that now she was doing MDI. I am sure you all know where this is going... when I mentioned Afrezza and all the benefits she could not beleive it! She had never heard of Afrezza. Immediately she put her daughter on the phone with her and as I described all the beneifits of using a CGM with Tresiba and Afrezza, the daughter started to cry as she had never heard of Afrezza and could not beleive there was a product out there that could change her life so drastically and improve her long term health prospects. So I am now going to drive 90 miles one way this weekend to visit them and give them a presentation and educate them before they go ask their doctor, just to make sure they are armed and eduated with enough information to push for Afrezza. One of the prime sources I have referred them to is AfrezzaJustBreathe, so thank you Compound for keeping it going... The Good and the Bad of this story is the obvious, and it is a story that seems to constantly be repeated... Enough said! GLTAL's Thank you. Well you give them this video please? He explains the medication and dosing so well. I Admit It, I Inhale! Inhaled & Other Newer Insulins (Jeremy Pettus, MD) www.youtube.com/watch?v=94HT41Hennk&list=PLN-L1716i5adlZPt0z6h6PVEI_9SgUj9K&index=6 |
|
|
|
Post by mannmade on Nov 8, 2019 10:28:16 GMT -5
Yes, I will Peppy. One pwd at a time...
|
|
|
|
Post by harryx1 on Nov 8, 2019 10:29:31 GMT -5
|
|
|
|
Post by buyitonsale on Nov 8, 2019 12:37:31 GMT -5
I blame our CMO for not being out there enough and not engaging and educating endocrinologists. His current strategy of "easiest job I have ever had" is not working.
His prior positions and experience should have yielded much more influence to date.
And the board should really focus on that as well.
|
|
|
|
Post by harryx1 on Nov 8, 2019 13:36:05 GMT -5
One more  |
|
|
|
Post by mannmade on Nov 8, 2019 14:07:45 GMT -5
Here's an interesting idea... What if Mannkind were to hire patient reps (one per targeted sales market) to focus just on patients as a way to coordinate and dovetail with medical/doctor reps. How many pateints could one rep see and instruct on dosing each year? Let's say 2 per day / 10 per week / 520 per year.
Now let's say there are 25 targeted markets (I have forgotten how many there actually are at this point) and these reps go to doctors offices to spend time answering questions and teaching proper titration at the offices of prescribing doctors.
I think their abiltiy to increase retention and to help with onboarding new patients would more than pay for itself.
|
|
|
|
Post by standup on Nov 8, 2019 14:32:08 GMT -5
Here's an interesting idea... What if Mannkind were to hire patient reps (one per targeted sales market) to focus just on patients as a way to coordinate and dovetail with medical/doctor reps. How many pateints could one rep see and instruct on dosing each year? Let's say 2 per day / 10 per week / 520 per year. Now let's say there are 25 targeted markets (I have forgotten how many there actually are at this point) and these reps go to doctors offices to spend time answering questions and teaching proper titration at the offices of prescribing doctors. I think their abiltiy to increase retention and to help with onboarding new patients would more than pay for itself. If they had started a similar approach just 1 year ago how would that work out? Two happy people on Afrezza each teach two new poeple how to correctly use the drug and after a month those four people each teach two people, etc. Two goes to 4 after the first month. Four goes to 8, 8 goes to 16, 16 goes to 32, 32 to 64, 64 to 128, 128 to 264, 264 to 528, 528 to 1056, 1056 to 2112, 2112 to 4224, 4224 to 8448. After 1 year there are 8448 people using Afrezza. Sure this is overly simplistic but really not too far a reach. Time for new leadership. |
|
|
|
Post by nylefty on Nov 8, 2019 14:46:39 GMT -5
Here's an interesting idea... What if Mannkind were to hire patient reps (one per targeted sales market) to focus just on patients as a way to coordinate and dovetail with medical/doctor reps. How many pateints could one rep see and instruct on dosing each year? Let's say 2 per day / 10 per week / 520 per year. Now let's say there are 25 targeted markets (I have forgotten how many there actually are at this point) and these reps go to doctors offices to spend time answering questions and teaching proper titration at the offices of prescribing doctors. I think their abiltiy to increase retention and to help with onboarding new patients would more than pay for itself. Wouldn't the FDA object to MannKind employees going beyond the label? If MannKind is severely limited in what it can say in commercials, patient reps would be too. Vdex doctors and NPs can go off label, but MannKind can not. |
|
|
|
Post by matt on Nov 8, 2019 15:06:34 GMT -5
Here's an interesting idea... What if Mannkind were to hire patient reps (one per targeted sales market) to focus just on patients as a way to coordinate and dovetail with medical/doctor reps. How many pateints could one rep see and instruct on dosing each year? Let's say 2 per day / 10 per week / 520 per year. Now let's say there are 25 targeted markets (I have forgotten how many there actually are at this point) and these reps go to doctors offices to spend time answering questions and teaching proper titration at the offices of prescribing doctors. I think their abiltiy to increase retention and to help with onboarding new patients would more than pay for itself. Wouldn't the FDA object to MannKind employees going beyond the label? If MannKind is severely limited in what it can say in commercials, patient reps would be too. Yes, FDA will get upset if the reps make product claims that are not on the label, but dose titration and proper usage in accordance with the label is fair game. As I recall either Sanofi or Mannkind hired diabetes nurse educators in the early days for this exact purpose. Getting any patient stabilized on any medication is often a trial and error process, and there is a lot that can be done without crossing lines that the FDA finds objectionable. The question is whether the additional marketing cost is justified by increased retention; if it is then great. However, I suspect continue lack of formulary coverage is a far bigger problem due to the very significant out-of-pocket expense incurred by the patient. |
|
|
|
Post by harryx1 on Nov 8, 2019 15:10:35 GMT -5
Here's an interesting idea... What if Mannkind were to hire patient reps (one per targeted sales market) to focus just on patients as a way to coordinate and dovetail with medical/doctor reps. How many pateints could one rep see and instruct on dosing each year? Let's say 2 per day / 10 per week / 520 per year. Now let's say there are 25 targeted markets (I have forgotten how many there actually are at this point) and these reps go to doctors offices to spend time answering questions and teaching proper titration at the offices of prescribing doctors. I think their abiltiy to increase retention and to help with onboarding new patients would more than pay for itself. Maybe a simpler idea of creating an educational video with a nurse practitioner / diabetes educator and user like UTHR did for Tyvaso and then creating a peer network site where users can go to get a mentor or help if needed... Patients could be given info with the prescription directing them to this info. www.youtube.com/watch?time_continue=675&v=Bz-lvYFQpgUwww.peernetwork.com/WTF does the CTO of Mannkind do anyways?  ?? |
|
|
|
Post by nylefty on Nov 8, 2019 15:39:19 GMT -5
Wouldn't the FDA object to MannKind employees going beyond the label? If MannKind is severely limited in what it can say in commercials, patient reps would be too. Yes, FDA will get upset if the reps make product claims that are not on the label, but dose titration and proper usage in accordance with the label is fair game. As I recall either Sanofi or Mannkind hired diabetes nurse educators in the early days for this exact purpose. Getting any patient stabilized on any medication is often a trial and error process, and there is a lot that can be done without crossing lines that the FDA finds objectionable. The question is whether the additional marketing cost is justified by increased retention; if it is then great. However, I suspect continue lack of formulary coverage is a far bigger problem due to the very significant out-of-pocket expense incurred by the patient. MannKind did post job openings for Nurse educators, but apparently that didn't work out. UPDATE From two and a half years ago: Mar 21, 2017 at 12:03pm madog365 said: Going to paraphrase from the Q4 earnings presentation some of the key initiatives that Mike laid out:
On the size of the salesforce: "approximately 3X of where we were last year in terms of where we expect to make impact. And we still have few more openings, I think, six or seven."
On nurse educators: "We transition to a per day nurse educator model. And so now we have almost 80 nurse educators across the country who will help to a per day in training and/or education in office"
On reality show sponsorship: "we’ve partnered with third-party, such as Charles Mattocks who’s putting a reality show on for diabetes on this Discovery Life in the summer. That will be one of the first time you will see our TV commercial aired. It’s part of our sponsorship. We are going to get exclusive commercials during that show."
On Damon Dash: "He has genuinely taken an interest in the product and with diabetes and educating others around their diabetes health. He’ll be launching something called Dash diabetes network over the coming weeks and there will be targeted content launching out of that process"
On in-doctor's office ads: I wanted to announce today the Outcome Health platform...You’ve got the TV in the doctor’s office....You have the billboard if you look on the left wall, there’s like electronic billboards that will rotate, and you have patient iPads in the office. So when you’re waiting for the doctor to come in, you have an iPad and in all those scenarios you will see a Afrezza branding and ads being placed. They have averaged over 155,000 doctors, obviously, we won’t be in all those offices. But we will be in a large percentage of our targets that have this capacity and capability in the office.
On social media: We’ll be partnering with a leading third-party portal who works with patients and doctors. They have 6 million people with diabetes in their network, 2.2 million unique visitors a month to the properties, and all 30,000 of our targets for doctors who will be also being engaged
|
|
|
|
Post by awesomo on Nov 8, 2019 16:18:15 GMT -5
CTO reports to the CEO, so if he's not doing his job, look up.
|
|
|
|
Post by od on Nov 8, 2019 16:38:14 GMT -5
Sure, we are all entitled to believe what we believe, but I am surprised by many who 'thumbed-up' this post. Am I missing something? (I am not interested in being lectured about the ways of the pharmaceutical industry swamp.) Try this, Afrezza never recovered from a botched launch that was as much MannKind's doing as any other organization or person. |
|
|
|
Post by mnholdem on Nov 8, 2019 17:00:09 GMT -5
IMO, that’s largely because to CEO’s focus is too narrow. The biggest problem with being promoted from middle management is that you remain stuck within one or two compartments.
The job of CEO is much bigger. I’m not talking about micromanaging the entire company. No sir! The CEO job entails having a grasp of how all the pieces fit together and then assembling the team that will carry it out.
Accountability to the CEO’s plan is key. Perhaps this is the reason behind the recent executive bonuses. The plan didn’t stretch the capabilities of the executive team.
|
|
??
